According to Zacks, “Innate Pharma S.A. is a commercial stage oncology-focused biotech company. It discovers and develops therapeutic antibodies for the treatment of cancer. The company’s commercial-stage product includes Lumoxiti. Innate Pharma S.A. is based in Marseille, France. “
Separately, HC Wainwright reiterated a “buy” rating and set a $11.50 price target on shares of Innate Pharma in a research note on Friday, March 25th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $9.90.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. boosted its stake in shares of Innate Pharma by 27.4% in the 1st quarter. BlackRock Inc. now owns 504,408 shares of the company’s stock worth $1,695,000 after buying an additional 108,335 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Innate Pharma by 41.9% in the 4th quarter. Bank of America Corp DE now owns 247,051 shares of the company’s stock worth $1,127,000 after buying an additional 72,951 shares during the last quarter. Balyasny Asset Management LLC purchased a new position in shares of Innate Pharma in the 3rd quarter worth approximately $1,157,000. Affinity Asset Advisors LLC purchased a new position in shares of Innate Pharma in the 3rd quarter worth approximately $771,000. Finally, Alps Advisors Inc. purchased a new position in Innate Pharma in the fourth quarter valued at approximately $429,000. Hedge funds and other institutional investors own 1.74% of the company’s stock.
Innate Pharma Company Profile (Get Rating)
Innate Pharma SA, a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers.
- Get a free copy of the StockNews.com research report on Innate Pharma (IPHA)
- Short-Covering Begins In Big Lots
- Agilent Technologies Is Bottoming But Don’t Buy It Yet
- Institutions Ring The Register On Toll Brothers Stock
- Dick’s Sporting Goods Falls Flat On Weak Guidance
- Two Retailers, One To Buy And One To Avoid
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.